The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. In January 2026, the company completed an $11.1 million private placement with Dr. Reddy's Laboratories (a strategic collaborator) investing $10 million.
Cyborg Score Rationale
Coya has a differentiated clinical-stage pipeline targeting significant unmet needs in neurodegenerative disease with a novel Treg-based immunology approach. Recent validation includes Phase 2 FDA trial acceptance and positive proof-of-concept data. However, as a pre-revenue clinical-stage biotech, the company faces execution risk and competitive pressures typical of the sector.
Top Insights
Clinical momentum: COYA 302 Phase 2 trial for ALS accepted by FDA in August 2025, with Health Canada CTA clearance in November 2025 expanding geographic reach
Positive proof-of-concept: FTD study with low-dose IL-2 and CTLA4-Ig showed clinical benefits in 9 patients, supporting therapeutic hypothesis
Strategic partnership validation: Dr. Reddy's Laboratories invested $10M in January 2026 private placement, signaling confidence in platform and providing runway
Large addressable market: Three neurodegenerative indications (ALS, FTD, Parkinson's) represent multi-billion dollar opportunities with high unmet medical needs
Named Competitors
Small molecule and antibody therapies — Traditional approaches to ALS and neurodegenerative disease